Summary:
QuidelOrtho is refocusing its molecular diagnostics strategy by discontinuing its Savanna platform and planning to acquire LEX Diagnostics for $100 million following FDA clearance.

Takeaways:

  1. Strategic Realignment: QuidelOrtho aims to strengthen its presence in point-of-care molecular diagnostics by pivoting to LEX Diagnostics’ faster, high-sensitivity platform.
  2. Savanna Platform Discontinued: The company will cease development of its Savanna system due to less favorable clinical trial results and market considerations.
  3. Pending Acquisition: The $100M acquisition of LEX Diagnostics is contingent on FDA 510(k) clearance and is expected to bolster QuidelOrtho’s competitive edge in decentralized diagnostics.

QuidelOrtho Corporation, a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs, and transfusion medicine, today announced a refocusing of its molecular diagnostics strategy. This strategy includes the intent to acquire full ownership of LEX Diagnostics after 510(k) clearance by the U.S. Food and Drug Administration (FDA) for consideration at closing of approximately $100 million and plans to discontinue the Company’s Savanna platform development.

LEX Diagnostics is a molecular diagnostics company developing products designed to enhance patient care by delivering clinical insights within minutes and at the time they are most valuable. LEX Diagnostics’ thermal cycling technology is designed to combine exceptional speed with high sensitivity, without compromising quality. LEX Diagnostics’ ultra-fast molecular platform can report positive results in approximately six minutes with a single multiplex test for the detection and differentiation of Flu A, Flu B and COVID-19, while negative results can be reported in approximately 10 minutes.1The LEX Diagnostics system integrates into point-of-care workflows, bringing the sensitivity of PCR to urgent care centers, physician office labs, hospitals and other decentralized settings at a competitive price.

“Since joining QuidelOrtho one year ago, we have been engaged in a comprehensive, continuous review of our strategy to drive shareholder value. This afternoon we announced a significant step to realign our product portfolio to drive future growth. Our intended acquisition of LEX Diagnostics will strengthen and accelerate our presence in point-of-care molecular diagnostics—one of the largest and fastest-growing segments in the diagnostics industry,” says Brian J. Blaser, president and chief executive officer, QuidelOrtho.

“In comparing the results of recent clinical trial data, investment requirements, and the significant market opportunity for both the Savanna and LEX Diagnostics platforms, we determined that LEX Diagnostics offers important performance advantages for customers and is better aligned with our strengths and opportunities for growth,” Blaser added.

Update on Savanna

QuidelOrtho plans to discontinue its Savanna platform development. This decision reflects several factors, including the recent results of the Savanna RVP4X clinical trial. The Company intends to work closely with its customers and partners to facilitate an orderly transition plan.

Featured Image: Leong Chee Onn | Dreamstime.com